drugset
drugset / Trial / NCT05731843

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

NCT05731843 ↗

Phase 1 Completed 32 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Drug-drug interaction study of Ruzasvir and Bemnifosbuvir

Timeline

Start
2023-01-30
Primary completion
2023-03-15
Completion
2023-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — —
Subject Ruzasvir Other / unclassified — —

Indications

No indication recorded.